Genprex Announces The Opening For Enrollment Of Its Phase 1/2 Acclaim-2 Clinical Trial Of REQORSA Immunogene Therapy In Combination With Keytruda To Treat Non-Small Cell Lung Cancer
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today
